Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switching to Paliperidone Palmitate Injection in Schizophrenia
NCT07075237Phase 4Not yet recruiting
- Sponsor
- Affiliated Brain Hospital of Nanjing Medical University
- Start
- Oct 2025
- Primary completion
- Oct 2026
- Modality
- Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 4 trial of paliperidone palmitate in schizophrenia, sponsored by Affiliated Brain Hospital of Nanjing Medical University. Planned start Oct 2025; status: not yet recruiting.
02
Drugs
paliperidone palmitate
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT07075237.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07075237.